Cambridge Network celebrates a milestone birthday as it turns 25, a testament to its success as an effective and established networking organisation, operating at the heart of the Cambridge cluster. The concept of a formalised Cambridge business networking community was a new idea when the Network was set up back in 1997 by an influential group comprising of the then Vice-Chancellor of the University, now Lord Broers, with entrepreneurs Hermann Hauser, David Cleevely, Nigel Brown, Fred Hallsworth and Anthony Ross. It began as a simple idea, of bringing together businesses and academia. Fast…

Your monthly round up of employee engagement activities, read more 

Click here to view the August edition of The Meeting Place

This transaction increases BioIVT's global network for collecting high-quality, disease-state biospecimens and extends its capabilities to deliver fresh biospecimens and produce cell products for drug and diagnostic development. BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it has acquired Fidelis Research, an 85-site clinical biospecimen collection network in Southeastern Europe with headquarters in Sofia, Bulgaria. Fidelis Research also possesses cell isolation capabilities and provides custom…

AMSBIO announce RNAdvantage – the first product in a new range of stabilization solutions that provide robust protection for your RNA samples at ambient temperature. Designed to protect and preserve RNA from most tissues, cultured cells, bacteria, and yeast for up to 14-days, RNAdvantage eliminates the traditional costs of flash freezing samples dry-ice shipping and freezer storage. From the point at which your tissue samples are collected, RNAdvantage permeates the tissue to stabilize the RNA at  room temperature. Samples can also be protected upon purification with no extra clean-…

Leading global drug development consultancy Boyds has added to its team with the appointment of experienced regulatory affairs professional Katherine Bowen in response to a rise in demand for its specialist regulatory services. With more than 14 years’ experience in regulatory affairs across both mid to large pharma and consultancies, Katherine joins Boyds as Senior Director of Regulatory Affairs. Katherine joins Boyds from regulatory consultancy DLRC where she was Head of Regulatory Teams and Principal Consultant leading a team of regulatory consultants as well as providing strategic and…

• Stevenage Bioscience Catalyst is leading the way by introducing the Warp It recycling scheme • The online reuse platform will enable occupier companies to donate and receive lab and office equipment, supplies and furniture • This will reduce costs and carbon footprints for occupiers Stevenage Bioscience Catalyst (SBC) is the first science park in the UK to sign up to the Warp It reuse platform. The platform enables companies to donate or receive surplus lab and office equipment, supplies and furniture. Dr Sally Ann Forsyth OBE, CEO at SBC, said, “Stevenage Bioscience Catalyst is home to…

VivoSTART GMP-grade leukopaks complement BioIVT’s GMP-grade human AB serum, providing a complete solution for advanced therapy development BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced the launch of its Good Manufacturing Practice (GMP-) grade VivoSTART™ leukopaks. Leukopaks contain concentrated white blood cells and are used to research and manufacture cell and gene therapies. “This GMP-grade leukopak product introduction underscores BioIVT’s commitment to being a high quality, global immune cell provider,” said…

Morgan Sindall Construction appointed as sole contractor to deliver Phase 2 of Unity Campus   • 90,000 sq ft of wet laboratory and office space available in 2023 to let as ‘shell & core’ or ‘fully fitted turnkey solution’ • Available as suites from 3,652 sq ft, up to a single-let building of 32,500 sq ft • First available newly constructed laboratories in the Cambridge cluster   Cambridge, 8th September 2022: Leading regional property investor and developer Howard Group has appointed Morgan Sindall Construction as sole contractor for the construction of three new wet laboratory…

Domainex Ltd., based in Cambridge UK, is a leading provider of integrated drug discovery services. As a result of the work carried out by Domainex during an in-house research programme to identify inhibitors of protein kinases TBK1 and IKK-epsilon, DMXD-011 has been nominated as a preclinical drug candidate. The molecule is orally-bioavailable and highly selective. The recent human ex-vivo data outlined below indicates this drug should be effective in the treatment of interferonopathies such as lupus, Sjögren’s syndrome, and scleroderma. The literature (e.g. Hasan et al, 2016, Louis et al,…